Research Article

Pharmacological Activation of Nrf2 by Rosolic Acid Attenuates Endoplasmic Reticulum Stress in Endothelial Cells

Karan Naresh Amin,1 Palanisamy Rajagru,2 Koustav Sarkar,1 M. R. Ganesh,3 Takayoshi Suzuki,4 Daoud Ali,5 and Ramkumar Kunka Mohanram1

1SRM Research Institute and Department of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, 603 203 Tamilnadu, India
2Department of Life Sciences, Central University of Tamil Nadu, Tiruvarur 610005, India
3Interdisciplinary Institute of Indian System of Medicine, SRM Institute of Science and Technology, Kattankulathur, 603 203 Tamilnadu, India
4Division Cellular and Gene Therapy Products, National Institute of Health Sciences, Setagaya-Ku, Tokyo, Japan
5Department of Zoology, College of Science King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia

Correspondence should be addressed to Ramkumar Kunka Mohanram; ramkumak@srmist.edu.in

Received 29 July 2020; Revised 17 November 2020; Accepted 5 December 2020; Published 9 April 2021

Academic Editor: Ayman Mahmoud

Copyright © 2021 Karan Naresh Amin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Endoplasmic reticulum (ER) plays a key role in the folding, modification, and trafficking of proteins. When the homeostasis of the ER is disturbed, un/misfolded proteins accumulate in the ER which leads to ER stress. Sustained ER stress results in apoptosis, which is associated with various diseases. Nuclear factor erythroid 2-related factor 2 (Nrf2) is a major transcription factor in redox homeostasis by regulating various genes associated with detoxification and cell-protective mechanisms. We found that Rosolic acid (RA) treatment dose-dependently activates Nrf2 in endothelial cells using the enzyme fragment complementation assay. The cytoprotective role of RA against ER stress-induced endothelial apoptosis and its molecular mechanism was explored in the present study. The Nrf2 and its target genes, as well as ER stress marker expressions, were measured by qPCR in ER stress-exposed endothelial cells. The contribution of Nrf2 in RA-mediated defense mechanism in endothelial cells was established by knockout studies using Nrf2-CRISPR/Cas9. The treatment with RA to ER stress-induced endothelial cells exhibited activation of Nrf2, as demonstrated by Nrf2 translocation and reduction of ER stress markers. We found that the Nrf2 knockout sensitized the endothelial cells against ER stress, and further, RA failed to mediate its cytoprotective effect. Proteomic studies using LC-MS/MS revealed that among the 1370 proteins detected, we found 296 differentially regulated proteins in ER stress-induced endothelial cells, and RA administration ameliorated 71 proteins towards the control levels. Of note, the ER stress in endothelial cells was attenuated by the treatment with the RA, suggesting the role of the Nrf2 activator in the pathological conditions of ER stress-associated diseases.

1. Introduction

The endothelium is the main component of the barricade for transporting many important biological compounds from the blood to the inner layer of cells. It is responsible for maintaining the vasculature by releasing various vasodilatory or vasoconstrictive factors like NO, endothelin-1, endothelium-derived hyperpolarizing factor, prostacyclin, and thromboxane [1]. Endothelial cells form a key component of the inflammatory and immune response and are the first cells to be activated during inflammation [2]. Endothelial apoptosis is a causative factor for diabetes and its vascular complications [3]. Understanding the transitions in apoptotic pathways may allow an improved understanding of the pathogenesis of disease and in the development of novel therapies [4, 5]. The currently available research highlights endothelial apoptosis as an initial event in the progression of certain diseases, including diabetes [6, 7].
The perturbations to the endothelial cell metabolic pathways lead to oxidative stress, endoplasmic reticulum (ER) stress, and inflammatory processes, which are the important contributors to endothelial apoptosis. ER stress has increased more attention as a crucial factor connecting and congregating molecular relationships among oxidative stress, endothelial cell dysfunction, and insulin resistance and, therefore, is considered an auspicious drug target for controlling diabetes and cardiovascular problems. Increasing evidence identifies the cross talk between oxidative stress and ER stress in the pathogenesis of diabetes and its complications [8, 9].

Numerous therapeutic strategies have been developed to combat ER stress-induced endothelial cell dysfunction [10–12]. Nrf2 is a major transcription factor in cellular defense, which acts as the chief watchdog of reduction-oxidation status and detoxification. Nrf2 is generally found in the cytoplasm under physiological conditions and connected with its negative regulator, Kelch-like ECH-associated protein1 (Keap1) [13, 14]. When the cells encounter oxidative stress or electrophiles, Nrf2 detaches from the Nrf2-Keap1 complex and translocates to the nucleus that activates the gene expression of antioxidant responsive element (ARE) to sustain cellular redox homeostasis [15]. In recent years, activation of Nrf2 by small molecules have been demonstrated as a new promising therapeutic approach for counteracting endothelial apoptosis [16–19]. It is interesting to note that Nrf2 is reported to associate with the UPR sensor called pancreatic endoplasmic reticulum kinase [20].

We have developed a high-throughput screening system based on luciferase complementation to screen Nrf2 activators and demonstrated its role against oxidative and cytokine stress in pancreatic beta cells through Nrf2 activation [21–25]. Few Nrf2 activators showed promising results against hyperglycemia-induced endothelial dysfunction (ED) [16]. Earlier, we reported quercetin, a potent Nrf2 activator that showed a cytoprotective effect on endothelial cells against ER stress-induced ED [26]. We have established a co-culture system to examine the cross talk between pancreatic beta cells and endothelial cells under ER stress and validated with a recognized ER stress regulator, quercetin [27].

Rosolic acid (RA), an important polyphenol extracted from Plantago asiatica L., has been demonstrated to increase the levels of Heme oxygenase-1 (HO-1) in endothelial cells [28]. The role of RA on ER stress-induced ED and its effect as a therapeutic agent are yet to be revealed. Hence, this study investigated the effects of RA against ER stress-induced toxicity in endothelial cells. Further, the role of Nrf2 on RA-mediated cytoprotection was also investigated using Nrf2 knockout endothelial cells by CRISPR/Cas9. To offer better understanding of the underlying molecular mechanism, we have carried out a proteome study on the RA-treated ER stress-induced endothelial cells using electrospray ionization tandem mass spectrometry (LC-MS/MS).

2. Materials and Methods

2.1. Cell Culture. The immortalized human umbilical vein endothelial hybrid cell line, EA.hy926 cells, was maintained in DMEM medium (Clonetics; Lonza Ltd, Basel, Switzerland) along with Fetal bovine serum (FBS, 10%) (v/v) (HyClone, Logan, UT, USA), penicillin (100 U/ml), and streptomycin (100 μg/ml). The cells were kept in a humidified 5% CO₂ atmosphere at 37°C. Immortalized cell lines offer significant logistical advantages over primary cells when used for in vitro studies.

2.2. ER Stress Induction. ER stress was induced in the EA.hy926 cells by exposing the cells to thapsigargin (TGP) (Sigma-Aldrich, USA) at a dose of 2 μM for two hours [29]. TGP inhibits sarcoplasmic/endoplasmic reticulum Ca²⁺-ATPase, leading to a depletion of ER calcium storage, resulting in the accumulation of unfolded proteins and inducer of cell death [30].

2.3. Assay of Cell Viability. The cell viability was measured using the MTT assay [31]. In brief, EA.hy926 cells (1x10⁴ cells/well) were cultured in a 96-well plate for 24 h at 37°C and then pretreated with RA (0-100 μM) for the next 24 h. After incubation, the medium was replaced by MTT solution (5 mg/ml) and kept in a humidified 5% CO₂ atmosphere for 4 h at 37°C. 100 μl of DMSO was added to all the wells and mixed thoroughly and read at 570 nm by a microplate reader (TECAN, Switzerland).

To study the effect of RA on ER stress-induced cell death, the cells were pretreated with RA (0-100 μM) for at least 24 h trailed by TGP (2 μM) for 2 h. The assay of MTT was then carried out as described above.

2.4. Quantitative Real-Time PCR (qRT-PCR). The molecular ER stress marker profiles, protein kinase R- (PKR-) like endoplasmic reticulum kinase (PERK), glucose-regulated protein (GRP) 78, C/ERB homologous protein (CHOP), activating transcription factor- (ATF-) 6, and Nrf2-regulated genes, including NAD(P)H quinone-oxidoreductase-1 (NQO1), heme oxygenase-1 (HO-1), catalase (CAT), and glutathione peroxidase (GPX), were performed using qRT-PCR (Bio-Rad, USA). The primers for the targeted genes were obtained from the genome DNA sequence database and NCBI human mRNA, and primers were designed using the primer3 plus, a free online bioinformatics tool, which is enumerated in Table 1. The cells were treated with different concentrations of RA for 24 h followed by thapsigargin (2 μM) for 2 h. The mRNA isolation was performed using the mRNA isolation kit (Qiagen, Germany) as per instructions provided by the manufacturer. The qRT-PCR was achieved using SYBR® Premix Ex Taq™ II (TaKaRa, Japan) as per the instructions provided by the manufacturer. The housekeeping gene Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the internal control for normalization, and the results are represented as relative fold change.

2.5. ARE-Luciferase Reporter Gene Assay. To confirm the Nrf2 activation potential, ARE promoter Responsive Luciferase Reporters such as GST-ARE-Luc and hNQO1-ARE-Luc reporter gene constructs were used in endothelial cells. Briefly, EA.hy926 cells were seeded and transfected with an ARE-Luc construct (500 ng/well) with the help of
Lipofectamine 2000. After 24 h, the transfected cells were administered with different amounts of RA (0-20 μM) and kept incubated for 8 h, and then the cells were assayed for luciferase activity by a luminometer (Promega, Madison, WI, USA). The luciferase activity was expressed in terms of relative fold variation compared to control cells.

### 2.6. Measurement of Intracellular Reactive Oxygen Species (ROS) Formation

2,7'-Dichlorofluorescin diacetate (DCFDA) (Sigma-Aldrich, USA) was used to measure the intracellular peroxides to assess the protective effect of RA against ROS formation in ER stress-induced endothelial cells. In brief, the endothelial cells were pretreated with RA (5 and 10 μM) for 24 h followed by exposure with 2 μM TPG for 2 h. Then, the cells were treated with DCFDA solution (25 μM) for 15 min, and the fluorescence was measured using flow cytometer (BD Biosciences, CA, USA) at 502 nm excitation and 550 nm emission wavelength.

### 2.7. Apoptosis Detection Using Annexin-V Labeling Assay by Flow Cytometry

Annexin-V-FITC was used to measure the apoptotic population percentage to evaluate the protective effect of RA against ER stress-induced endothelial cells. Briefly, the cells were harvested and centrifuged for 3 minutes at 1500 rpm. The cells were then stained with Annexin-V-FITC and determined using flow cytometer (BD Biosciences, CA, USA).

### 2.8. CRISPR/Cas9-Mediated Knockout of Nrf2 in Human Endothelial Cells

To confirm the role of RA on Nrf2-mediated protection, Nrf2-KO endothelial cells were generated using the CRISPR/Cas9 gene-editing tool. EA.hy926 cells were transfected with Nrf2-CRISPR/Cas9-GFP plasmid (sc-400017, Santa Cruz, USA). GFP+ cell expression was completely assessed in a randomized design. One-way ANOVA followed by Tukey’s post hoc test was subjected using the SPSS version 17.0 software (SPSS Inc., Chicago, IL, USA). All outcomes were reported as mean ± SD of at least independent tests of triplicates and P ≤ 0.05 was measured as statistically significant.

### 2.12. Statistical Analysis

All experimental studies were completely achieved in a randomized design. One-way ANOVA followed by Tukey’s post hoc test was subjected using the SPSS version 17.0 software (SPSS Inc., Chicago, IL, USA). All outcomes were reported as mean ± SD of at least independent tests of triplicates and P ≤ 0.05 was measured as statistically significant.

### 3. Results

#### 3.1. Cytoprotective Effect of RA on TPG-Stimulated ER Stress in Endothelial Cells

To evaluate the cytotoxic activity of RA in endothelial cells, cells were exposed to different

| S. No. | Gene   | Forward       | Reverse       |
|-------|--------|---------------|---------------|
| 1     | NRF2   | TGTAGATGACAATGAGGTTTC | ACTGACCTGTAGTATGAGCAAA |
| 2     | GPx    | TTCCCGTGCAACGAGTTTG | TGCACCTGCACCTTCGAA |
| 3     | SOD    | GAAGTTGTGGGGGAGGATTA | ACATTGCCAAGGTCTCCACAC |
| 4     | NQO1   | AGCATGGAAGAAAGCGCCTGG | TCAGTTGGAGGACTTGCC |
| 5     | HO1    | GGGATTCCTTGGCTGCTGCT | AACTGAGGATGCTGAAGGGG |
| 6     | GRP78  | GCCGTGGGTCGTTCAAGA | CAGCACGGTCTATTCCAGT |
| 7     | PERK   | GAACACAGCATGAGACAAGAG | GAGATGACCAAGAAGACG |
| 8     | CHOP   | GTACCTAGTGTCACCTGCTGCT | TGGAAATCTGGAGGATGG |
| 9     | ATF 6  | CGGAGCCACTGAAGAGAATA | TTTGAGCTTGGTGCTG |
| 10    | GAPDH  | AAGAAGGTGTGGGAGGAGG | GTCAGGAGTGGAGGAGG |

Table 1: List of primers and its sequences used for the study.
concentrations of RA for 24 h, and viable cells were determined by the MTT assay. The outcomes are presented in Figure 1(a). The cytoprotective effect of RA against TPG-induced apoptosis in endothelial cells was accessed using the MTT assay. Endothelial cells treated with TPG at 2 μM for 2 h showed a 35% reduction in cell viability. However, the cells pretreated with different concentrations of RA (2.5-25 μM) showed a dose-dependent increase in cell viability, and the protective effect was found to be maximum at 5 and 10 μM RA concentrations (Figure 1(b)), and at 25 μM, it was toxic to the cells.

3.2. Nrf2 Activation Potential of RA in Endothelial Cells. To determine the Nrf2 activation by RA, its binding potential to nuclear ARE and activation of its downstream regulatory genes, reporter gene constructs, and their cell-based assays, GST-ARE-Luc and hNQO1-ARE-Luc were employed. Various concentrations of RA treated on endothelial cells, which were later harvested and measured the luciferase activity. A dose-dependent elevated reporter luciferase signals of GST and NQO1 were observed in RA-treated cells, presented in Figure 2(a). Furthermore, dose-dependent elevated levels of Nrf2 in RA-treated endothelial cells are also noticed in Figure 2(b). Based on the outcome, the study confirms the potential role of RA on the activation of Nrf2 in endothelial cells.

3.3. Efficacy of RA on Nrf2 Activation and Translocation in ER Stress-Stimulated Endothelial Cells. To study the role of RA on Nrf2-mediated protection of endothelial cells against
ER stress, we evaluated the impact of RA on the Nrf2 expression and its downstream target genes in endothelial cells. RA treatment resulted in increased levels of Nrf2 in ER stress-induced endothelial cells as assessed by qPCR and western blotting (Figures 3(a) and 3(b)). Further, RA-mediated Nrf2 activation was confirmed by Nrf2 translocation from cytosol to the nucleus. The RA-treated cells showed decreased levels of Nrf2 in cytosolic fraction while increased levels in the nuclear fraction as demonstrated by western blotting. Further, the accumulation of cytosolic Nrf2 with a concomitant decrease in nuclear Nrf2 was observed in the TPG-treated endothelial cells was reversed upon RA pretreatment (Figure 3(c)). This confirms the role of RA-mediated Nrf2 activation against ER stress-induced ED.

3.4. Efficacy of RA on Nrf2 Activation and Its Downstream Regulation in ER Stress-Stimulated Endothelial Cells. To study the effects of RA on Nrf2 downstream target genes, GPxs, CAT, HO-1, and NQO1 expressions were studied. Upon treatment with TPG, the expressions of GPx, CAT, and NQO1 were downregulated, and HO-1 was marginally upregulated. Pretreatment with RA (5 and 10 μM) effectively upregulated the expression of all the above-mentioned Nrf2 downstream genes in a dose-respective manner (Figures 4(a)–4(d)). RA treatment alone increased the expression of antioxidant genes, showing its potential antioxidant property.

Further, to validate the potential of RA on reducing the oxidative stress via Nrf2 signaling, we have determined the enzyme activities of SOD, CAT, and GPxs in endothelial cells. The activity of SOD in endothelial cells with TPG-induced ER stress was found to be significantly decreased (0.71 units/mg protein), which was restored upon pretreatment with 10 μM RA (1.12 units/mg protein) to near-normal levels (1.21 units/mg protein). A similar pattern of results was observed for both CAT and GPx activities with a significant reduction of enzyme activity in the TPG-treated endothelial cells with enzyme activity 30.19 μmol/min/mg protein and 123.11 μmol/min/mg protein, respectively. RA pretreatment dose-dependently showed improvement in CAT and GPx activities in endothelial cells. The quantitative results proved that RA also protected ER stress-induced endothelial cells against oxidative damage (Table 2).

3.5. Efficacy of RA against ER Stress in Endothelial Cells Assessed by ER Stress Markers. The protective effect of RA against TPG-induced ER stress in endothelial cells was evaluated by studying the expression of ER stress markers PERK, ATF-6, GRP78, and CHOP. All the tested ER stress gene expression was upregulated in TPG-treated cells, which confirm the stimulation of ER stress. Interestingly, pretreatment with RA (5 and 10 μM) exhibited a dose-respective reduction in the PERK, ATF-6, and GRP78 expression but not CHOP expression (Figures 5(a)–5(d)). RA treatment alone did not show any significant variation in the level of ER stress gene expressions even after 24 h exposure in endothelial cells. Further, RA-mediated protection against ER stress was confirmed by the levels of the decreased ER chaperone GRP-78 by western blotting (Figure 5(e)).

3.6. Effect of RA against ROS Formation against ER Stress in Endothelial Cells as Assessed by DCFDA Assay Using Flow Cytometry. Intracellular ROS sensitive fluorescent probe DCFDA was used to evaluate whether RA could inhibit TPG-induced intracellular ROS generation in endothelial cells. As seen in Figure 6, there was a right shift in DCF peak in TPG- (Figure 6(c)) treated endothelial cells compared to control (Figure 6(a)), which confirm the increased free radical generation. Interestingly, a dose-dependent shift towards left was observed in the group pretreated with 5 (Figure 6(d)) and 10 (Figure 6(e)) μM RA, respectively, proving the effect of RA in reducing intracellular ROS generation and thus protecting the endothelial cells against oxidative stress.

3.7. Antiapoptotic Efficacy of RA against ER Stress-Stimulated Endothelial Apoptosis. Annexin-V-FITC labeling assay by flow cytometry were implemented to examine the antiapoptotic property of RA against TPG-induced ER stress in endothelial cells. The apoptotic cell population was elevated by 43.87% (Figure 7) in TPG-treated cells. A dose-dependent reduction by 34.28% and 17.49% was observed in 5 and 10 μM on RA pretreatment, respectively. There was no significant change seen in the cell population treated with RA alone compared with untreated EA.hy926 cells. This shows that the RA protects endothelial cells against apoptosis induced by ER stress.

3.8. Development of Nrf2-Knockout Endothelial Cells Using CRISPR/Cas9. To determine whether the protective efficacy of RA was facilitated via activation of Nrf2, we have developed Nrf2-knockout endothelial cells using CRISPR/Cas9. The knockout cells were subjected to flow cytometry analysis, and a comparable level of GFP expression was recorded in both control and Nrf2 KO EA.hy926 cells, which shows equal transfection efficiency of both the plasmids. However, Nrf2 expression was completely lost in Nrf2 KO plasmid-transfected EA.hy926 cells when compared to the scrambled transfected control cells, as seen in Figure 8. Further, this result was validated using western blot analysis, where a complete reduction in the Nrf2 level was recorded in KO cells, and those cells were used for the further mechanistic study.

3.9. Efficacy of RA on TPG-Stimulated ER Stress in Nrf2 KO Endothelial Cells. MTT assay was performed to check the modulation in the cytoprotective effect of RA on TPG-induced ER stress in Nrf2 KO cells. Increased sensitivity to apoptosis upon ER stress was observed in Nrf2 KO cells, which was confirmed by a 59.2% reduction in the cell viability upon exposure to TPG. Further pretreatment with different concentrations of RA (2.5–25 μM) for 24 h failed to protect the cells against ER stress (Figure 9(a)). This confirms that RA protects the endothelial cells against ER stress through the stimulation of the Nrf2 signaling pathway.

3.10. Effect of RA on ER Stress Markers in Nrf2-Knockout Endothelial Cells. Further, we compared the effect of RA on the ER stress marker expressions, PERK, ATF-6, GRP-78,
Figure 3: Effect of Rosolic acid on level of Nrf2 gene expression (a) by qRT-PCR analysis and protein level (b) by western blotting in ER stress-induced EA.hy926 cells. (c) The effect of Rosolic acid on Nrf2 translocation from cytosol to the nucleus by western blotting in EA.hy926 cells under ER stress. Data are represented as mean ± SD of three independent experiments. *Significant compared with the control group. #Significant compared with TPG group; P < 0.05 determined by one-way ANOVA followed by Tukey’s post hoc test (0, control; TPG, thapsigargin; 2.5, 5, 10, and 25, concentrations of Rosolic acid in μM).
and CHOP in both Nrf2 wild-type and Nrf2 KO cells subjected to ER stress. RA-pretreated cells exhibited augmented ER stress marker expressions when compared to control cells. RA-mediated protection against ER stress was not observed in Nrf2 KO cells unlike in wild-type EA.hy926 cells where the protection was evident (Figure 9(b)).

3.11. Molecular Mechanism of RA-Mediated Protection against ER Stress through Proteomic Analysis. To study the molecular mechanism using proteomic analysis using LC-MS/MS on a Q Exactive mass spectrometer, we have taken three groups, including control (Cont), TPG-treated endothelial cells (TPG), and RA-treated TPG-induced endothelial cells (TPG+RA). The results revealed that among the identified 1370 proteins, 35.03% of the proteins were known with one peptide, 18.61% with two peptides, 10.58% with three peptides, 6.27% with four peptides, and 27% of proteins with more than five peptides. The proteins with two or more peptides were considered for further analysis. We found 296 proteins were differentially expressed with twofold or more change and two or more peptides in TPG-treated cells when compared to the control in which 143 downregulated

![Graphs showing changes in enzyme activities](image)

**Figure 4:** Effect of Rosolic acid on Nrf2 downstream targets such as (a) catalase (CAT), (b) glutathione peroxidase (GPx), (c) heme oxygenase-1 (HO-1), and (d) NAD(P)H:quinone-oxidoreductase-1 (NQO-1) expression in ER stress-induced EA.hy926 cells by qRT-PCR analysis. Data are represented as mean ± SD of three independent experiments. *Significant compared with Control group. \^Significant compared with TPG group; \(P<0.05\) determined by one-way ANOVA followed by Tukey's post hoc test (0, control; TPG, thapsigargin; 2.5, 5, 10, and 25, concentrations of Rosolic acid in \(\mu\text{M}\)).

**Table 2:** Effect of Rosolic acid on activities of enzymatic antioxidants in ER stress-induced EA.hy926 cells.

| Groups | SOD (units/mg protein) | CAT (\(\mu\text{mol/min/mg protein}\)) | GPx (\(\mu\text{mol/min/mg protein}\)) |
|--------|------------------------|--------------------------------------|--------------------------------------|
| Control | 1.21 ± 0.04            | 39.62 ± 0.8                          | 150.51 ± 9.61                       |
| RA (10 \(\mu\text{M}\)) | 1.43 ± 0.09 **          | 42.21 ± 4.4                          | 192.04 ± 13.72 **                   |
| TPG (2 \(\mu\text{M}\)) | 0.71 ± 0.21 **          | 30.19 ± 1.1 **                       | 123.11 ± 5.69 **                   |
| RA (5 \(\mu\text{M}\)) + TPG (2 \(\mu\text{M}\)) | 0.81 ± 0.12 ***         | 31.62 ± 2.7 ***                     | 118.06 ± 7.78 ***                  |
| RA (10 \(\mu\text{M}\)) + TPG (2 \(\mu\text{M}\)) | 1.12 ± 0.16##          | 33.41 ± 0.2 **##                     | 135.59 ± 9.89 **##                |

Data are represented as mean ± SD of three independent experiments. *Significant compared with the control group. \^Significant compared with TPG group; \(P<0.05\) determined by one-way ANOVA followed by Tukey's post hoc test.
and 153 upregulated. The STRING 11 online web tool was used to generate protein-protein interaction networks of differentially regulated proteins, with the settings of "MCL inflation parameter (3.0) and medium confidence (0.4)" (Figure 10(a)). We have identified eight major protein interaction network clusters, which are mainly involved in protein synthesis machinery, protein transport, stress response proteins, protein-folding proteins, and ER proteins.

The cellular organelle localization of the differentially regulated proteins was identified as 39.3% from the nucleus, 13.1% from the endoplasmic reticulum, 6.6% from the mitochondria, 8.2% from the Golgi apparatus, and 30.3% from the vacuoles using PANTHER. Further, the class of differentially regulated proteins was found that 16.9% proteins were associated with cytoskeletal proteins, 15.1% with translational proteins, 9.6% with membrane traffic proteins, 8.4% with chaperones, and 14.5% in protein modifying enzymes (Figure 10(b)).

Further, the differentially regulated proteins were subjected to DAVID for their annotation. We found a total of 17 clusters with an enrichment score of more than 3. We have considered the clusters with an enrichment score of more than 10. The top three cellular components are occupied by "cell-cell adhesion proteins" with an enrichment score of 17.2, "Cell Chaperone" has an enrichment score of 13.35, and "GTP-binding" has an enrichment score of 10.88 (Table 3).

The list of DAVID–KEGG pathways of differentially regulated proteins are depicted in Table 4. 10.6% of the

---

**Figure 5: Effect of Rosolic acid against ER stress as assessed by ER stress markers such as (a) protein kinase R- (PKR-) like endoplasmic reticulum kinase (PERK), (b) activating transcription factor- (ATF-) 6, (c) glucose-regulated protein (GRP) 78, and (d) C/ERB homologous protein (CHOP) expression in ER stress-induced EA.hy926 cells qRT-PCR analysis. (e) The effect of Rosolic acid on GRP-78 and CHOP by western blotting in EA.hy926 cells under ER stress. Data are represented as mean ± SD of three independent experiments. *Significant compared with the control group. #Significant compared with TPG group; P < 0.05 determined by one-way ANOVA followed by Tukey’s post hoc test.**

---

and 153 upregulated. The STRING 11 online web tool was used to generate protein-protein interaction networks of differentially regulated proteins, with the settings of “MCL inflation parameter (3.0) and medium confidence (0.4)” (Figure 10(a)). We have identified eight major protein interaction network clusters, which are mainly involved in protein synthesis machinery, protein transport, stress response proteins, protein-folding proteins, and ER proteins.

The cellular organelle localization of the differentially regulated proteins was identified as 39.3% from the nucleus, 13.1% from the endoplasmic reticulum, 6.6% from the mitochondria, 8.2% from the Golgi apparatus, and 30.3% from the vacuoles using PANTHER. Further, the class of differentially regulated proteins was found that 16.9% proteins were associated with cytoskeletal proteins, 15.1% with translational proteins, 9.6% with membrane traffic proteins, 8.4% with chaperones, and 14.5% in protein modifying enzymes (Figure 10(b)).

Further, the differentially regulated proteins were subjected to DAVID for their annotation. We found a total of 17 clusters with an enrichment score of more than 3. We have considered the clusters with an enrichment score of more than 10. The top three cellular components are occupied by “cell-cell adhesion proteins” with an enrichment score of 17.2, “Cell Chaperone” has an enrichment score of 13.35, and “GTP-binding” has an enrichment score of 10.88 (Table 3).

The list of DAVID–KEGG pathways of differentially regulated proteins are depicted in Table 4. 10.6% of the
proteins belong to protein processing in the endoplasmic reticulum. The other classes of proteins include RNA transport, proteasome, antigen processing and presentation, phagosome, estrogen signaling pathway, leukocyte transendothelial migration, adherent junction, and AMPK signaling pathway.

4. Discussion

Though several approaches have been established to improve the endothelial functions, drugs that can effectively treat microvascular complications are limited. This study was performed to determine RA, a polyphenol isolated from the rhizome of *Plantago asiatica* L. which can be used as a therapeutic agent to treat hyperglycemia-induced ER stress and endothelial dysfunction. We provided the first line of evidence that RA attenuates ER stress-induced endothelial apoptosis. Further, we also provide evidence that attenuation of ER stress and apoptosis is a result of the activation of Nrf2 and its signaling network.

Generally, endothelial cells are metabolically dynamic, contributing to various physiological mechanisms, including

Figure 6: Analysis of reactive oxygen species formation in ER stress-induced EA.hy926 cells measured by flow cytometry using H2DCFDA assay. Cells were pretreated with 5 and 10 μg for 24 hours and then treated with thapsigargin for 2 hours, and then the cells were incubated with 25 μM of DCFDA solution for 15 min and then harvested. After washing, the cells were subjected to flow cytometric analysis.
maintenance of blood fluidity, permeability, angiogenesis, and the control of vasomotor tone [34]. Oxidative stress, cytokines, and ER stress often cause endothelial cell injury, which disrupts ER homeostasis ensuing the accretion of unfolded or misfolded proteins, and thus activation of an adaptive response called UPR. The main function of UPR is to decrease ER stress and prolong cell endurance. If ER stress is extended, the signaling shifts from prosurvival to prodeath, which leads to ER stress-stimulated apoptosis [35, 36]. The ER function disruption has often been connected to the progression of numerous illnesses, including diabetes [37–39]. Although the causative role is yet to be established, the
CRISPR/Cas9 Knockout plasmid

- **U6 promoter**: drives expression of gRNA
- **20 nt sequence**: guides Cas9 to a specific target location in the genomic DNA
- **gRNA scaffold**: helps Cas9 bind to target DNA
- **Termination signal**
- **Nuclear localization signal**
- **2A peptide**: allows production of both Cas9 and GFP from the same CBh promoter
- **CBh (chicken β-Actin hybrid) promoter**: drives expression of Cas9
- **NLS**: Nuclear localization signal
- **SpCas9 ribonuclease**

---

**Figure 8**: CRISPR/Cas9-mediated knockout of Nrf2 expression in EA.hy926 cells. The endothelial cells were transfected with Nrf2-CRISPR (a). CAS9-GFP plasmid and GFP+ cells expression were screened using FACS (b). Western blot analysis for Nrf2-expression was performed to confirm successful Nrf2-depletion (c).
**Figure 9:** Effect of Rosolic acid on ER stress-induced toxicity in Nrf2 KO and wild-type EA.hy926 cells. (a) Cytoprotective effect of Rosolic acid in wild-type and Nrf2 KO EA.hy926 cells against thapsigargin-induced toxicity as assessed by MTT assay. (b) Effect of Rosolic acid on ER stress-induced toxicity in Nrf2 KO and wild-type cells as assessed by ER stress markers, (b) protein kinase R- (PKR-) like endoplasmic reticulum kinase (PERK), (c) activating transcription factor- (ATF-) 6, (d) glucose-regulated protein (GRP) 78, and (e) C/ERB homologous protein (CHOP) gene expression levels in ER stress-induced in wild-type and Nrf2 KO EA.hy926 cells using thapsigargin by qRT-PCR analysis. Data are represented as mean ± SD of three independent experiments. *Significant compared with the control group. #Significant compared with TPG group; P < 0.05 determined by one-way ANOVA followed by Tukey’s post hoc test.
Figure 10: Continued.
underlying mechanisms by which ER dysfunction can recruit or stimulate a disease state have been suggested [40]. Few investigations have established that ER stress promotes apoptosis through the caspase activation in endothelial cells [41, 42]. Earlier investigations have also revealed that endothelial cells are highly susceptible to ER and oxidative stress, a pathological cause of endothelial injury [43]. Besides, a rate-limiting enzyme of the hexosamine pathway, fructose-6 phosphate amidotransferase, is overexpressed in diabetic settings, which contributes ER stress through inducing UPR-related gene expressions that eventually recruit proinflammatory and apoptosis mechanisms [44]. Also, increased levels of ER stress markers, CHOP, GRP-78, PERK, and ATF-6 are seen in cells under ER stress [45]. Mozzini et al. revealed high levels of GRP-78 and CHOP in the PBMCs of chronic T2DM patients to be linked to the loss of Nrf2/ARE defense [46]. The ER and oxidative stress responses were correlated to PERK-mediated activation of ATF4 and Nrf2 [47]. Yang et al. demonstrated the effects of palmitic acid toxicity on apoptosis of H9c2 cardiomyocytes, uncovered the corelation between ER and oxidative stress apoptotic signaling pathways, and further showed the ameliorative effect of N-acetylcysteine against oxidative and ER stress-induced cell apoptosis [48]. Recently, ER stress has been shown to have a direct link with the inflammatory response pathway. Lei et al. showed that the administration of lipopolysaccharide results in the activation of ER stress as assessed by marker protein expression GRP78 and CHOP along with the increased levels of proinflammatory cytokines such as IL-1β, IL-6, IL-8, and TNF-α in mouse granulosa cells. Also, inhibition of ER stress by 4-phenylbutyrate (4-PBA) reduced the expression of proinflammatory cytokines and ER stress markers, CHOP and GRP78 [49].

A well-known ER stress inducer, thapsigargin, is an appropriate irreversible inhibitor of sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA) which induces an elevation of calcium levels and causes fragmentation of DNA, resulting in cell demise by triggering apoptotic mechanisms or alteration in architecture of the cell [50]. In the current investigation, the two ER stress markers CHOP and GRP78 were induced in thapsigargin-exposed endothelial cells. Rosolic acid is known for its beneficial effects on the cardiovascular system [28]. RA-induced HO-1 in endothelial cells thereby showed antioxidant, anti-inflammatory, and antiapoptotic effects in several pathophysiological mechanisms stimulated cardiac damage [28]. In the current study, we indicated that RA defends endothelial cells against apoptosis and ER stress, ensuring a favorable effect on the vascular system. The underlying mechanisms explaining the function of RA in endothelial cells and their regulation of physiological processes have not been explored yet. This is the opening line of proof highlighting the role of RA-mediated Nrf2 activation in endothelial cells. Nrf2 is a chief regulator of the cellular stress response, and the activation of Nrf2 by small molecules has shown protective effects against the development of ED both in vitro and in vivo studies [16]. In the present study, RA activated Nrf2, thereby triggering its downstream regulations, including HO-1,
Table 3: List of DAVID annotation clusters with enrichment score above 10.

| Category         | Term                                                                 | Count | P value          | Fold enrichment | Bonferroni | Benjamini | FDR  |
|------------------|----------------------------------------------------------------------|-------|------------------|-----------------|------------|-----------|------|
| Annotation cluster 1 | GOTERM_MF_DIRECT                                                      |       |                  |                 |            |           |      |
|                  | Cadherin binding involved in cell-cell adhesion                      | 33    | 2.1E-19          | 7.9             | 9.1E-17     | 3.0E-17   | 3.0E-16|
|                  | GOTERM_CC_DIRECT                                                      |       |                  |                 |            |           |      |
|                  | Cell-cell adherens junction                                          | 33    | 5.3E-19          | 7.7             | 2.1E-16     | 3.0E-17   | 7.4E-16|
|                  | GOTERM_BP_DIRECT                                                      |       |                  |                 |            |           |      |
|                  | Cell-cell adhesion                                                   | 28    | 2.2E-15          | 7.2             | 3.5E-12     | 1.8E-12   | 3.7E-12|
|                  | **Enrichment score:** 17.2                                            |       |                  |                 |            |           |      |
| Annotation cluster 2 | UP_KEYWORDS                                                          |       |                  |                 |            |           |      |
|                  | Chaperone                                                            | 32    | 1.4E-25          | 13.3            | 3.6E-23     | 1.2E-23   | 1.8E-22|
|                  | GOTERM_MF_DIRECT                                                      |       |                  |                 |            |           |      |
|                  | Unfolded protein binding                                             | 26    | 3.1E-23          | 16.4            | 1.3E-20     | 6.5E-21   | 4.3E-20|
|                  | GOTERM_BP_DIRECT                                                      |       |                  |                 |            |           |      |
|                  | Protein folding                                                      | 30    | 2.4E-22          | 11.6            | 3.8E-19     | 3.8E-19   | 4.0E-19|
|                  | **Enrichment score:** 13.35                                           |       |                  |                 |            |           |      |
| Annotation cluster 3 | UP_KEYWORDS                                                          |       |                  |                 |            |           |      |
|                  | GTP-binding                                                          | 30    | 1.1E-16          | 7.3             | 2.9E-14     | 4.1E-15   | 1.4E-13|
|                  | UP_SEQ_FEATURE                                                       |       |                  |                 |            |           |      |
|                  | Nucleotide phosphate-binding region: GTP                            | 28    | 1.1E-15          | 7.4             | 8.7E-13     | 8.7E-13   | 1.7E-12|
|                  | UP_KEYWORDS                                                          |       |                  |                 |            |           |      |
|                  | Nucleotide-binding                                                   | 64    | 2.0E-15          | 3.0             | 5.1E-13     | 6.4E-14   | 2.6E-12|
|                  | GOTERM_MF_DIRECT                                                      |       |                  |                 |            |           |      |
|                  | GTPase activity                                                      | 26    | 5.4E-15          | 7.7             | 2.3E-12     | 4.5E-13   | 7.5E-12|
|                  | **Enrichment score:** 10.88                                           |       |                  |                 |            |           |      |
| Annotation cluster 3 | UP_SEQ_FEATURE                                                       |       |                  |                 |            |           |      |
|                  | Lipid moiety-binding region: S-geranylgeranyl cysteine               | 15    | 5.1E-11          | 11.4            | 4.0E-8      | 2.0E-8    | 7.8E-8 |
|                  | **Enrichment score:** 9.1E-12                                          |       |                  |                 |            |           |      |
| Annotation cluster 3 | UP_SEQ_FEATURE                                                       |       |                  |                 |            |           |      |
|                  | Short sequence motif: effector region                               | 14    | 2.8E-10          | 11.4            | 2.2E-7      | 7.3E-8    | 4.3E-7 |
|                  | **Enrichment score:** 7.3E-8                                          |       |                  |                 |            |           |      |
| Annotation cluster 3 | UP_SEQ_FEATURE                                                       |       |                  |                 |            |           |      |
|                  | Lipid moiety-binding region: S-geranylgeranyl cysteine               | 15    | 5.1E-11          | 11.4            | 4.0E-8      | 2.0E-8    | 7.8E-8 |
|                  | **Enrichment score:** 9.1E-12                                          |       |                  |                 |            |           |      |
| Annotation cluster 3 | UP_SEQ_FEATURE                                                       |       |                  |                 |            |           |      |
|                  | Short sequence motif: effector region                               | 14    | 2.8E-10          | 11.4            | 2.2E-7      | 7.3E-8    | 4.3E-7 |
|                  | **Enrichment score:** 7.3E-8                                          |       |                  |                 |            |           |      |
| Annotation cluster 3 | UP_SEQ_FEATURE                                                       |       |                  |                 |            |           |      |
|                  | Lipid moiety-binding region: S-geranylgeranyl cysteine               | 15    | 5.1E-11          | 11.4            | 4.0E-8      | 2.0E-8    | 7.8E-8 |
|                  | **Enrichment score:** 9.1E-12                                          |       |                  |                 |            |           |      |
NQO1, GPx, and CAT. Further, we have used GST-ARE-Luc and hNQO1-ARE-Luc reporter gene constructs to confirm the RA-mediated Nrf2 activation potential of RA in EA.hy926 cells and recorded a dose-dependent increase in the Nrf2 expression levels. In agreement with the report published by Foresti et al., RA dose-dependently increased the expression of HO-1 [28]. The Nrf2 translocation from cytosol to nucleus further conformed the Nrf2 activation potential of RA as demonstrated by western blot.

Our data demonstrated TPG exposure decreased expression of HO-1, NQO1, GPx, and CAT, and a dose-dependent increase was observed in the RA pretreatment. Also, the activities of SOD, CAT, and GPx have further confirmed the role of RA in Nrf2 mediated cytoprotective action against oxidative stress in endothelial cells. It is well known that Nrf2 is a master regulator of detoxifying enzymes exerting the effect through its different downstream pathways targeting HO-1, NQO1, GPx, and CAT. Maamoun et al. have already proved that HO-1 independently shows a protective effect in HUVECs against ER stress-mediated endothelial apoptosis and also impaired angiogenesis in a high-lucose environment [51]. Along with HO-1, Chen et al. reported that Nrf2 downstream targets like GPx and glutathione (GSH) showed protection of endothelial cells against H$_2$O$_2$-induced cytotoxicity [52]. It was evidenced that under persistent high glucose and more prominently in oscillating high glucose conditions, there was a high increase in the apoptotic population of Primary Human Coronary Artery Endothelial Cells (HCAEC) accompanied by the suppressed expression of Nrf2 and HO-1 [53]. NQO1 and HO-1 have also been implicated in promoting angiogenesis which are reported in diabetic wound healing in various in vitro and in vivo models [54]. The role of SOD, CAT, and GPx against oxidative stress has been demonstrated in many vascular complications [55, 56]. Many studies have reported the association of reduced SOD activity and increased vascular oxidative stress and also has been implicated in the vascular disorders with ED as the underlying cause [57–60]. Our earlier studies confirmed that pterostilbene, an Nrf2 activator, conferred protection against oxidative stress by elevating the levels of Nrf2 and its downstream genes and against cytokine stress [22, 24]. Further, the proteomic profiling of pancreatic tissue isolated from pterostilbene treated mice demonstrated that the majority of differentially regulated proteins were associated with oxidative and ER stress pathways [61].

In the current study, we observed a greater Nrf2 expression and downstream targets and significant inhibition in the expression of PERK, CHOP, and GRP78 in RA-treated endothelial cells. Our outcomes show that the cytoprotective effect of RA on endothelial apoptosis was mediated by the activation of Nrf2.

To determine whether the protective efficacy of RA was facilitated via activation of Nrf2, we have developed Nrf2 knockout endothelial cells using CRISPR/Cas9. We found a very minimal expression of Nrf2 in knockout cells. The probable reason could be the biological plasticity which rescues target Nrf2 activity in CRISPR knockouts. This concept has been observed in three truncated targets, BRD4, DNMT1, and NGLY1, which revealed partial preservation of protein function even after knock out by CRISPR/Cas9 [Smits, 2019 #2260]. The Nrf2 cytoprotective adaptive response has evolved to be a powerful protective strategy for organisms against exposure to various insults. This Nrf2 signaling can provide plasticity in the cellular response to a wide array of chemical agents.
Since RA failed to show the protective effect against ER stress in Nrf2 KO by CRISPR/Cas9 in this study, it cannot be ruled out that the increased expression of Nrf2 caused inhibition of ER stress markers such as GRP78 and CHOP, thus restoring ER homeostasis. Additional investigations are needed to extrapolate the function of RA in ER stress-stimulated apoptosis in animal models.

There are many studies that have linked decreased Nrf2 activity leads to increased oxidative damage, leading to many pathophysiological disorders, including obesity, diabetes mellitus, and atherosclerosis which are the major contributors of cardiovascular disorders [62]. Few other Nrf2 activators have also shown promising therapeutics against hyperglycemia and ED as demonstrated by Wang et al. Cinnamaldehyde, an Nrf2 activator, preserved nitric oxide (NO) levels and upregulated Nrf2 levels in human umbilical vein endothelial cells (HUVECs) and proved to be a potential therapeutic agent against diabetes-induced ED [17]. The Nrf2 activators such as curcumin, resveratrol, and sulforaphane have also been explored as adjuvants against diabetic complications [64–66]. Ding proved that the dietary ellagic acid showed a protective effect against oxidative stress developed ED and atherosclerosis through the Nrf2 activation pathway in human umbilical vein endothelial cells and diabetic mice [67].

In our results, we found that RA has a protective effect against ER stress and that there are concentration-dependent effects. Furthermore, we used LC-MS/MS to evaluate the molecular mechanism of endothelial cells. By analyzing the differentially regulated proteins in RA-pretreated endothelial cells exposed to ER stress, we found that the differentially regulated proteins were mainly enriched for proteins from the protein-folding machinery and cell-cell adhesion proteins. It has been reported that under pathophysiological stimuli, the ER homeostasis has been disrupted and leads to the accumulation of misfolded and or unfolded proteins in the ER until correctly folded or demolished [68]. Sustained ER stress has been associated with ED. In the present study, treatment of endothelial cells with RA improved its function by inhibiting ER stress through the regulation of protein-folding machinery.

The adenosine monophosphate-activated protein kinase (AMPK) is a central protein kinase that has been reported to enhance the various protecting cells under different stress stimuli such as hypoxia [69], glucose deprivation [70], and hypertrophy [71] and act as a potential target for resisting atherosclerosis. It has been reported that the key target cells in cardiovascular endothelial cells or smooth muscle cells are directly or indirectly controlled by AMPK [72]. Few reports demonstrated that activation of AMPK is connected with protein synthesis inhibition through elongation factor 2 (eEF2) phosphorylation in heart muscles [73, 74]. Terai et al. reported that AMPK possibly inhibits the signaling of ER-linked apoptosis in heart muscles [73]. Zimmermann et al. demonstrated AMPK employs a positive effect in mouse embryonic fibroblast-associated signaling of Nrf2/heme oxygenase-1 (HO-1) [75]. Numerous studies suggested that the collaboration of Nrf2 and AMPK contributes to the progressive signaling networks [76, 77]. The AMPK activation has been found to stimulate the unfolded protein response and reduce ER stress in many stressors [78]. Metformin, a known stimulator of AMPK inhibits GRP78 and phosphorylates eukaryotic initiation factor-2α resulting in a reduction of THP-induced ER stress [78]. The silencing of NRF2 during oxidative stress ensuing a constant activation of AMPK contributes to hyperactivation of autophagy [79]. Our results revealed that the RA-facilitated defense against ER stress might be through theamelioration of the AMPK pathway. In addition to these pathways, other significantly changed pathways were cell-cell adhesion proteins, GTP-binding proteins, stress response proteins, proteasomal pathway, RNA transport, etc. To our understanding, this is the preliminary pilot study that validates that RA exerts a direct impact on alleviating ER stress-mediated alterations in defending endothelial cells.

5. Conclusions
In conclusion, Rosolic acid is a potent Nrf2 activator and is protective against ER stress-induced endothelial apoptosis. This protective effect of Rosolic acid is attributed to the induction of Nrf2 and can be developed into a possible therapeutic intervention against ED in diabetes and related cardiovascular diseases. Further in vivo studies are essential to confirm the effect of Rosolic acid in diabetes.

Data Availability
The complete data of the findings of this study are available in “Results” and also from the corresponding author.

Conflicts of Interest
We declare that we have no competing financial interests and personal relationships with other people or organizations that can inappropriately influence our work. There is no professional or other personal interests of any nature or kind in any product, service, and/or company that could be construed as influencing the position presented in, or the review of, the manuscript.

Authors’ Contributions
Karan Naresh Amin (KNA), Palanisamy Rajaguru (PR), Koustav Sarkar (KS), Mr. Ganesh (MRG), Ramkumar Kunka Mohanram (RKM), Daoud Ali (DA), and Takayoshi Suzuki (TS) conceived the study. KNA, PR, KS, MRG, RKM, DA, and TS are responsible for writing—review and editing. PR and RKM visualized
and supervised the study. RKM was responsible for project administration. RKM acquired funding. All authors have read and agreed to the published version of the manuscript.

Acknowledgments

The study was funded by the Science and Engineering Research Board (SERB) (Grant No. EMR/2016/006196), Government of India. The authors gratefully acknowledge the facilities provided by “SRM-DBT Partnership Platform for Contemporary Research Services and Skill Development in Advanced Life Sciences Technologies” (Grant No. BT/PR12987/INF/22/205/2015).

Supplementary Materials

Figure S1: description of detailed methodology of proteomics. (Supplementary Materials)

References

[1] A. Sandoo, J. J. C. S. Veldhuijzen van Zanten, G. S. Metsios, D. Carroll, and G. D. Kitas, “The endothelium and its role in regulating vascular tone,” Open Cardiovascular Medicine Journal, vol. 4, no. 1, pp. 302–312, 2010.

[2] J. S. Pober and W. C. Sessa, “Evolving functions of endothelial cells in inflammation,” Nature Reviews. Immunology, vol. 7, no. 10, pp. 803–815, 2007.

[3] R. E. Gilbert, “Endothelial loss and repair in the vascular complications of diabetes: pathogenetic mechanisms and therapeutic implications,” Circulation Journal, vol. 77, no. 4, pp. 849–856, 2013.

[4] J. C. Choy, D. J. Granville, D. W. Hunt, and B. M. McManus, “Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis,” Journal of Molecular and Cellular Cardiology, vol. 33, no. 9, pp. 1673–1690, 2001.

[5] Z. Mallat and A. Tedgui, “Apoptosis in the vasculature: mechanisms and functional importance,” British Journal of Pharmacology, vol. 130, no. 5, pp. 947–962, 2000.

[6] A. Avogaro, M. Albiero, L. Menegazzo, S. de Kreutzenberg, and G. P. Fadini, “Endothelial dysfunction in diabetes: the role of reparatory mechanisms,” Diabetes Care, vol. 34, Supplement 2, pp. S285–S290, 2011.

[7] A. Avogaro, G. P. Fadini, A. Gallo, E. Pagnin, and S. de Kreutzenberg, “Endothelial dysfunction in type 2 diabetes mellitus,” Nutrition, Metabolism, and Cardiovascular Diseases, vol. 16, Suppl 1, pp. S39–S45, 2006.

[8] S. Z. Hasnain, “Endoplasmic reticulum and oxidative stress in immunopathology: understanding the crosstalk between cellular stress and inflammation,” Clinical & Translational Immunology, vol. 7, no. 7, article e1035, 2018.

[9] H. Maamoun, T. Benameur, G. Pintus, S. Munsamy, and A. Agouni, “Crosstalk between oxidative stress and endoplasmic reticulum (er) stress in endothelial dysfunction and aberrant angiogenesis associated with diabetes: a focus on the protective roles of heme oxygenase (ho)-1,” Frontiers in Physiology, vol. 10, 2019.

[10] G. Amadio, O. Molteo, R. Faraonio, and P. Remondelli, “Targeting the endoplasmic reticulum unfolded protein response to counteract the oxidative stress-induced endothelial dys-

function,” Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 4946289, 13 pages, 2018.

[11] Y. Dong, C. Fernandes, Y. Liu et al., “Role of endoplasmic reticulum stress signalling in diabetic endothelial dysfunction and atherosclerosis,” Diabetes & Vascular Disease Research, vol. 14, no. 1, pp. 14–23, 2016.

[12] M. Toral, R. Jimenez, M. Romero et al., “Role of endoplasmic reticulum stress in the protective effects of pparbeta/delta activation on endothelial dysfunction induced by plasma from patients with lupus,” Arthritis Research & Therapy, vol. 19, no. 1, 2017.

[13] J. A. David, W. J. Rijfkin, P. S. Rabbani, and D. J. Ceradini, “The nrf2/keap1 pathway and oxidative stress as a therapeutic target in type ii diabetes mellitus,” Journal Diabetes Research, vol. 2017, article 4826724, pp. 1–15, 2017.

[14] E. Bhakkiyalakshmi, D. Sireesh, P. Rajaguru, R. Paulmurugan, and K. M. Ramkumar, “The emerging role of redox-sensitive nrf2-keap1 pathway in diabetes,” Pharmacological Research, vol. 91, pp. 104–114, 2015.

[15] R. Li, Z. Jia, and H. Zhu, “Regulation of nrf2 signaling,” Reactive Oxygen Species (Apex), vol. 8, no. 24, pp. 312–322, 2019.

[16] A. Karan, E. Bhakkiyalakshmi, R. Jayasuriya, D. V. L. Sarada, and K. M. Ramkumar, “The pivotal role of nuclear factor erythroid 2-related factor 2 in diabetes-induced endothelial dysfunction,” Pharmacological Research, vol. 153, article 104601, 2020.

[17] A. Sharma, L. Rizky, N. Stefanovic et al., “The nuclear factor (erythroid-derived 2)-like 2 (nrf2) activator dh404 protects against diabetes-induced endothelial dysfunction,” Cardiovascular Diabetology, vol. 16, no. 1, 2017.

[18] Z. Ungvari, Z. Bagi, A. Feher et al., “Resveratrol confers endothelial protection via activation of the antioxidant transcription factor nrf2,” American Journal of Physiology. Heart and Circulatory Physiology, vol. 299, no. 1, pp. H18–H24, 2010.

[19] H. Mao, T. Tao, X. Wang et al., “Zedoarondiol attenuates endothelial cells injury induced by oxidized low-density lipoprotein via nrf2 activation,” Cellular Physiology and Biochemistry, vol. 48, no. 4, pp. 1468–1479, 2018.

[20] L. Cominacci, C. Mozzini, U. Garbin et al., “Endoplasmic reticulum stress and nrf2 signaling in cardiovascular diseases,” Free Radical Biology & Medicine, vol. 88, no. Part B, pp. 233–242, 2015.

[21] K. M. Ramkumar, T. V. Sekar, K. Foygel, B. Elango, and R. Paulmurugan, “Reporter protein complementation imaging assay to screen and study nrf2 activators in cells and living animals,” Analytical Chemistry, vol. 85, no. 15, pp. 7542–7549, 2013.

[22] E. Bhakkiyalakshmi, D. Shalini, T. V. Sekar, P. Rajaguru, R. Paulmurugan, and K. M. Ramkumar, “Therapeutic potential of pterostilbene against pancreatic beta-cell apoptosis mediated through nrf2,” British Journal of Pharmacology, vol. 171, no. 7, pp. 1747–1757, 2014.

[23] B. Elango, S. Dornadula, R. Paulmurugan, and K. M. Ramkumar, “Pterostilbene ameliorates streptozotocin-induced diabetes through enhancing antioxidant signaling pathways mediated by nrf2,” Chemical Research in Toxicology, vol. 29, no. 1, pp. 47–57, 2016.

[24] D. Sireesh, M. R. Ganesh, U. Dhamodharan et al., “Role of pterostilbene in attenuating immune mediated devastation of pancreatic beta cells via nrf2 signaling cascade,” The Journal of Nutritional Biochemistry, vol. 44, pp. 11–21, 2017.
L. Tolosa, M. T. Donato, and M. J. Gomez-Lechon, "Morin activates the nrf2-are pathway and reduces oxidative stress-induced DNA damage in pancreatic beta cells," European Journal of Pharmacology, vol. 801, pp. 9–18, 2017.

N. Suganya, E. Bhakthiyalakshmi, S. Suriyanarayanan, R. Paulmurugan, and K. M. Ramkumar, "Quercetin ameliorates tunicamycin-induced endoplasmic reticulum stress in endothelial cells," Cell Proliferation, vol. 47, no. 3, pp. 231–240, 2014.

N. Suganya, K. P. Mani, D. Sireesh et al., "Establishment of pancreatic microenvironment model of er stress: Quercetin attenuates β-cell apoptosis by invoking nitric oxide-cgmp signaling in endothelial cells," The Journal of Nutritional Biochemistry, vol. 55, pp. 142–156, 2018.

R. Foresti, M. Hoque, D. Monti, C. J. Green, and R. Motterlini, "Differential activation of heme oxygenase-1 by chalcones and Rosolic acid in endothelial cells," The Journal of Pharmacological and Experimental Therapeutics, vol. 312, no. 2, pp. 686–693, 2005.

C. M. Olsowski and F. Urano, "Measuring ER stress and the unfolded protein response using mammalian tissue culture system," Methods in Enzymology, vol. 490, pp. 71–92, 2011.

P. Sehgal, P. Szalai, C. Olesen et al., "Inhibition of the sarco/endoplasmic reticulum (ER) Ca²⁺-ATPase by thapsigargin analogs induces cell death via ER Ca²⁺ depletion and the unfolded protein response," The Journal of Biological Chemistry, vol. 292, no. 48, pp. 19656–19673, 2017.

L. Tolosa, M. T. Donato, and M. J. Gomez-Lechon, "General cytotoxicity assessment by means of the MTT assay," Methods in Molecular Biology, vol. 1250, pp. 333–348, 2015.

H. Sim Choi, J. Woo Kim, Y. N. Cha, and C. Kim, "A quantitative nitroblue tetrazolium assay for determining intracellular superoxide anion production in phagocytic cells," Journal of Immunassay & Immunochromatography, vol. 27, no. 1, pp. 31–44, 2006.

C. J. Weydert and J. J. Cullen, "Measurement of superoxide dismutase, catalase and glutathione peroxidase in cultured cells and tissue," Nature Protocols, vol. 5, no. 1, pp. 51–66, 2010.

P. Rajendran, T. Rengarajan, J. Thangavel et al., "The vascular endothelium and human diseases," International Journal of Biological Sciences, vol. 9, no. 10, 2013.

C. M. Scull and I. Tabas, "Mechanisms of er stress-induced apoptosis in atherosclerosis," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 12, pp. 2792–2797, 2011.

E. Szegedi, S. E. Logue, A. M. Gorman, and A. Samali, "Mediators of endoplasmic reticulum stress-induced apoptosis," EMBO Reports, vol. 7, no. 9, pp. 880–885, 2006.

L. Ozcan and I. Tabas, "Role of endoplasmic reticulum stress in metabolic disease and other disorders," Annual Review of Medicine, vol. 63, no. 1, pp. 317–328, 2012.

H. P. Harding and D. Ron, "Endoplasmic reticulum stress and the development of diabetes: a review," Diabtes, vol. 51, Supplement 3, pp. S455–S461, 2002.

X. Lei, S. Zhang, S. E. Barbour et al., "Spontaneous development of endoplasmic reticulum stress that can lead to diabetes mellitus is associated with higher calcium-independent phospholipase a2 expression: a role for regulation by srebp-1," The Journal of Biological Chemistry, vol. 285, no. 9, pp. 6693–6705, 2010.

J. H. Lin, P. Walter, and T. S. Yen, "Endoplasmic reticulum stress in disease pathogenesis," Annual Review of Pathology, vol. 3, no. 1, pp. 399–425, 2008.

R. Sano and J. C. Reed, "ER stress-induced cell death mechanisms," Biochimica et Biophysica Acta, vol. 1833, no. 12, pp. 3460–3470, 2013.

N. Sovoljova, S. Healy, A. Samali, and S. E. Logue, "Stressed to death - mechanisms of ER stress-induced cell death," Biological Chemistry, vol. 395, no. 1, pp. 1–13, 2014.

S. Lenna, R. Han, and M. Trojanowska, "Endoplasmic reticulum stress and endothelial dysfunction," IUBMB Life, vol. 66, no. 8, pp. 530–537, 2014.

A. T. Sage, L. A. Walter, Y. Shi et al., "Hexosamine biosynthesis pathway flux promotes endoplasmic reticulum stress, lipid accumulation, and inflammatory gene expression in hepatic cells," American Journal of Physiology. Endocrinology and Metabolism, vol. 298, no. 3, pp. E499–E511, 2010.

A. Samali, U. Fitzgerald, S. Deegan, and S. Gupta, "Methods for monitoring endoplasmic reticulum stress and the unfolded protein response," International Journal of Cell Biology, vol. 2010, Article ID 830307, 11 pages, 2010.

C. Mozzini, U. Garbin, C. Stranieri et al., "Endoplasmic reticulum stress and nfrf2 repression in circulating cells of type 2 diabetic patients without the recommended glycemic goals," Free Radical Research, vol. 49, no. 3, pp. 244–252, 2015.

S. B. Cullinan and J. A. Diehl, "Coordination of ER and oxidative stress signaling: the perk/nfrf2 signaling pathway," The International Journal of Biochemistry & Cell Biology, vol. 38, no. 3, pp. 317–322, 2006.

L. Yang, G. Guan, L. Lei, J. Liu, L. Cao, and X. Wang, "Oxidative and endoplasmic reticulum stress are involved in palmitic acid-induced b9c2 cell apoptosis," Bioscience Reports, vol. 39, no. 5, 2019.

L. Lei, J. Ge, H. Zhao, X. Wang, and L. Yang, "Role of endoplasmic reticulum stress in lipopolysaccharide-inhibited mouse granulosa cell estradiol production," The Journal of Reproduction and Development, vol. 65, no. 5, pp. 459–465, 2019.

Y. Kaneko and A. Tsukamoto, "Thapsigargin-induced persistent intracellular calcium pool depletion and apoptosis in human hepatoma cells," Cancer Letters, vol. 79, no. 2, pp. 147–155, 1994.

H. Maamoun, M. Zachariah, J. H. McVey, F. R. Green, and A. Agouni, "Heme oxygenase (ho)-1 induction prevents endoplasmic reticulum stress-mediated endothelial cell death and impaired angiogenic capacity," Biochemical Pharmacology, vol. 127, pp. 46–59, 2017.

J. S. Chen, P. H. Huang, C. H. Wang et al., "Nrf2-mediated heme oxygenase-1 expression, an antioxidant-independent mechanism, contributes to anti-atherogenesis and vascular protective effects of ginkgo biloba extract," Atherosclerosis, vol. 214, no. 2, pp. 301–309, 2011.

Z. Ungvari, L. Bailey-Downs, T. Gautam et al., "Adaptive induction of nf-e2-related factor-2-driven antioxidant genes in endothelial cells in response to hyperglycemia," American Journal of Physiology. Heart and Circulatory Physiology, vol. 300, no. 4, pp. H1133–H1140, 2011.

A. Jindam, V. G. Yerra, and A. Kumar, "Nrf2: a promising trove for diabetic wound healing," Annals of Translational Medicine, vol. 5, no. 23, 2017.

J. A. Leopold and J. Loscalzo, "Oxidative enzymopathies and vascular disease," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 7, pp. 1332–1340, 2005.
[56] J. M. Li and A. M. Shah, “Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology,” *American Journal of Physiology. Regulatory, Integrative and Comparative Physiology*, vol. 287, no. 5, pp. R1014–R1030, 2004.

[57] U. Landmesser, R. Merten, S. Spiekermann, K. Buttner, H. Drexl, and B. Hornig, “Vascular extracellular superoxide dismutase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilatation,” *Circulation*, vol. 101, no. 19, pp. 2264–2270, 2000.

[58] S. Hamed, B. Brenner, A. Aharon, D. Daoud, and A. Roguin, “Progenitor cell function in type 2 diabetes mellitus,” *Cardiovascular Diabetology*, vol. 8, no. 1, 2009.

[59] D. D. Lund, Y. Chu, J. D. Miller, and D. D. Heistad, “Protective effect of extracellular superoxide dismutase on endothelial function during aging,” *American Journal of Physiology. Heart and Circulatory Physiology*, vol. 296, no. 6, pp. H1920–H1925, 2009.

[60] D. D. Guttermann, H. Miura, and Y. Liu, “Redox modulation of vascular tone: focus of potassium channel mechanisms of dilation,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 25, no. 4, pp. 671–678, 2005.

[61] S. Dornadula, S. Thiruppathi, R. Palanisamy, D. Umapathy, T. Suzuki, and R. K. Mohanram, “Differential proteomic profiling identifies novel molecular targets of peroxisome pathology against experimental diabetes,” *Journal of Cellular Physiology*, vol. 234, no. 3, pp. 1996–2012, 2018.

[62] R. M. da Costa, D. Rodrigues, C. A. Pereira et al., “Nrf2 as a potential mediator of cardiovascular risk in metabolic diseases,” *Frontiers in Pharmacology*, vol. 10, 2019.

[63] F. Wang, C. Pu, P. Zhou et al., “Cinnamaldehyde prevents endothelial dysfunction induced by high glucose by activating nrf2,” *Cellular Physiology and Biochemistry*, vol. 36, no. 1, pp. 315–324, 2015.

[64] N. Parsamanesh, M. Moossavi, A. Bahrami, A. E. Butler, and A. Sahebkar, “Therapeutic potential of curcumin in diabetic complications,” *Pharmacological Research*, vol. 136, pp. 181–193, 2018.

[65] V. Ciddi and D. Dodda, “Therapeutic potential of resveratrol in diabetic complications: in vitro and in vivo studies,” *Pharmacological Reports*, vol. 66, no. 5, pp. 799–803, 2014.

[66] S. Yamagishi and T. Mastui, “Protective role of sulphoraphane against vascular complications in diabetes,” *Pharmaceutical Biology*, vol. 54, no. 10, pp. 2329–2339, 2016.

[67] Y. Ding, B. Zhang, K. Zhou et al., “Dietary ellagic acid improves oxidant-induced endothelial dysfunction and atherosclerosis: role of nrf2 activation,” *International Journal of Cardiology*, vol. 175, no. 3, pp. 508–514, 2014.

[68] M. Wang and R. J. Kaufman, “Protein misfolding in the endoplasmic reticulum as a conduit to human disease,” *Nature*, vol. 529, no. 7586, pp. 326–335, 2016.

[69] P. T. Mungai, G. B. Waypa, A. Jairaman et al., “Hypoxia triggers AMPK activation through reactive oxygen species-mediated activation of calcium release-activated calcium channels,” *Molecular and Cellular Biology*, vol. 31, no. 17, pp. 3531–3545, 2011.

[70] Y. Ren and H. M. Shen, “Critical role of AMPK in redox regulation under glucose starvation,” *Redox Biology*, vol. 25, article 101154, 2019.

[71] F. Mailleux, C. Beauloye, J. L. Balligand, S.orman, and L. Bertrand, “Studying the role of AMPK in cardiac hypertrophy and protein synthesis,” *Methods in Molecular Biology*, vol. 1732, pp. 321–342, 2018.

[72] Q. Xu and L. Y. Si, “Protective effects of AMP-activated protein kinase in the cardiovascular system,” *Journal of Cellular and Molecular Medicine*, vol. 14, no. 11, pp. 2604–2613, 2010.

[73] K. Terai, Y. Hiramota, M. Masaki et al., “AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress,” *Molecular and Cellular Biology*, vol. 25, no. 21, pp. 9554–9575, 2005.

[74] G. J. Browne, S. G. Finn, and C. G. Proud, “Stimulation of the amp-activated protein kinase leads to activation of eukaryotic elongation factor 2 kinase and to its phosphorylation at a novel site, serine 398,” *The Journal of Biological Chemistry*, vol. 279, no. 13, pp. 12220–12231, 2004.

[75] K. Zimmermann, J. Baldinger, B. Mayerhofer, A. G. Atanasov, V. M. Dirsch, and E. H. Heiss, “Activated ampk boosts the nrf2/ho-1 signaling axis—a role for the unfolded protein response,” *Free Radical Biology & Medicine*, vol. 88, no. Part B, pp. 417–426, 2015.

[76] X. L. Chen, G. Dodd, S. Thomas et al., “Activation of nrf2/are pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression,” *American Journal of Physiology. Heart and Circulatory Physiology*, vol. 290, no. 5, pp. H1862–H1870, 2006.

[77] E. H. Heiss, D. Schachner, E. R. Werner, and V. M. Dirsch, “Active nrf-c2-related factor (nrf2) contributes to keep endothelial no synthase (enos) in the coupled state: role of reactive oxygen species (ros), enos, and heme oxygenase (ho-1) levels,” *The Journal of Biological Chemistry*, vol. 284, no. 46, pp. 31579–31586, 2009.

[78] H. Kim, S. Y. Moon, J. S. Kim et al., “Activation of amp-activated protein kinase inhibits er stress and renal fibrosis,” *American Journal of Physiology. Renal Physiology*, vol. 308, no. 3, pp. F226–F236, 2015.

[79] M. Kosztelnik, A. Kurucz, D. Papp et al., “Suppression of AMPK/aak-2 by NRF2/SKN-1 down-regulates autophagy during prolonged oxidative stress,” *The FASEB Journal*, vol. 33, no. 2, pp. 2372–2387, 2019.